ES2664611T3 - Tratamiento del edema de médula ósea (edema) con polisacáridos polisulfatados - Google Patents
Tratamiento del edema de médula ósea (edema) con polisacáridos polisulfatados Download PDFInfo
- Publication number
- ES2664611T3 ES2664611T3 ES12741560.2T ES12741560T ES2664611T3 ES 2664611 T3 ES2664611 T3 ES 2664611T3 ES 12741560 T ES12741560 T ES 12741560T ES 2664611 T3 ES2664611 T3 ES 2664611T3
- Authority
- ES
- Spain
- Prior art keywords
- pentosan polysulfate
- bone marrow
- treatment
- pps
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010051763 Bone marrow oedema Diseases 0.000 title claims abstract description 57
- 150000004676 glycans Chemical class 0.000 title claims abstract description 28
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 28
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title claims description 32
- 206010030113 Oedema Diseases 0.000 title description 3
- 229940043138 pentosan polysulfate Drugs 0.000 claims abstract description 90
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 9
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 19
- 238000007918 intramuscular administration Methods 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 159000000000 sodium salts Chemical class 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000011269 treatment regimen Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 abstract description 5
- 229960003820 pentosan polysulfate sodium Drugs 0.000 abstract 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 30
- 208000002193 Pain Diseases 0.000 description 25
- 230000003902 lesion Effects 0.000 description 19
- 210000000988 bone and bone Anatomy 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 201000008482 osteoarthritis Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 210000005065 subchondral bone plate Anatomy 0.000 description 8
- 208000014674 injury Diseases 0.000 description 7
- 208000034656 Contusions Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000017234 Bone cyst Diseases 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000000399 orthopedic effect Effects 0.000 description 4
- 241000283086 Equidae Species 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 210000003689 pubic bone Anatomy 0.000 description 3
- 210000004061 pubic symphysis Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010064269 Bone marrow oedema syndrome Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 2
- 206010018735 Groin pain Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 206010031149 Osteitis Diseases 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 208000018339 bone inflammation disease Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004439 collateral ligament Anatomy 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- -1 pentosan polysulfate Chemical class 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000010300 Genu Varum Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 206010062061 Knee deformity Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 210000001037 metacarpus Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011900325A AU2011900325A0 (en) | 2011-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides | |
| AU2011900325 | 2011-02-02 | ||
| PCT/AU2012/000091 WO2012103588A1 (en) | 2011-02-02 | 2012-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2664611T3 true ES2664611T3 (es) | 2018-04-20 |
Family
ID=46602012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12741560.2T Active ES2664611T3 (es) | 2011-02-02 | 2012-02-02 | Tratamiento del edema de médula ósea (edema) con polisacáridos polisulfatados |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9101650B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2670412B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5883458B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101840079B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103415293B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012212398B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2826166C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2670412T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2664611T3 (cg-RX-API-DMAC7.html) |
| MY (1) | MY164728A (cg-RX-API-DMAC7.html) |
| NO (1) | NO2670412T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2670412T (cg-RX-API-DMAC7.html) |
| SG (1) | SG192238A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI520740B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012103588A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015059177A1 (en) * | 2013-10-22 | 2015-04-30 | Cell Receptor Ug | Sulfated polysaccharides for use in the treatment of cancer |
| CA3071585A1 (en) * | 2017-08-04 | 2019-02-07 | Paradigm Biopharmaceuticals Ltd | Treatment of bone marrow pathologies with polysulfated polysaccharides |
| US11911413B2 (en) | 2018-02-16 | 2024-02-27 | Proteobioactives Pty Limited | Methods and compositions for the treatment of pain and/or inflammation |
| KR102796937B1 (ko) * | 2018-02-28 | 2025-04-15 | 패러다임 바이오파마슈티컬스 리미티드 | 다황화된 다당류를 이용한 수술 후 관절통의 치료 |
| JP2022512662A (ja) | 2018-10-10 | 2022-02-07 | パラダイム バイオファーマシューティカルズ リミテッド | ポリ硫酸化多糖を用いた疼痛の治療 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| US6593310B1 (en) * | 2000-11-21 | 2003-07-15 | Arthropharm Pty. Ltd. | Treatment of osteoporosis |
| US6564083B2 (en) * | 2000-12-18 | 2003-05-13 | Hoffmann-La Roche Inc. | Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis |
| DE10225551A1 (de) * | 2002-06-06 | 2003-12-24 | Schering Ag | Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind |
| CN101939417B (zh) | 2007-12-04 | 2014-02-05 | 蛋白生物动力私人有限公司 | 祖细胞的保护和它们的分化的调节 |
-
2012
- 2012-02-01 TW TW101103252A patent/TWI520740B/zh active
- 2012-02-02 ES ES12741560.2T patent/ES2664611T3/es active Active
- 2012-02-02 NO NO12741560A patent/NO2670412T3/no unknown
- 2012-02-02 WO PCT/AU2012/000091 patent/WO2012103588A1/en not_active Ceased
- 2012-02-02 DK DK12741560.2T patent/DK2670412T3/en active
- 2012-02-02 KR KR1020137022985A patent/KR101840079B1/ko active Active
- 2012-02-02 CA CA2826166A patent/CA2826166C/en active Active
- 2012-02-02 JP JP2013552065A patent/JP5883458B2/ja active Active
- 2012-02-02 SG SG2013058268A patent/SG192238A1/en unknown
- 2012-02-02 CN CN201280007433.9A patent/CN103415293B/zh active Active
- 2012-02-02 AU AU2012212398A patent/AU2012212398B2/en active Active
- 2012-02-02 US US13/983,406 patent/US9101650B2/en active Active
- 2012-02-02 MY MYPI2013701355A patent/MY164728A/en unknown
- 2012-02-02 EP EP12741560.2A patent/EP2670412B1/en active Active
- 2012-02-02 PT PT127415602T patent/PT2670412T/pt unknown
-
2015
- 2015-07-02 US US14/790,476 patent/US9861657B2/en active Active
-
2017
- 2017-09-29 US US15/720,884 patent/US10610542B2/en active Active
-
2020
- 2020-02-25 US US16/800,245 patent/US11406660B2/en active Active
-
2022
- 2022-07-05 US US17/857,420 patent/US20220362284A1/en not_active Abandoned
-
2023
- 2023-11-21 US US18/515,823 patent/US20240156858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO2670412T3 (cg-RX-API-DMAC7.html) | 2018-06-02 |
| US11406660B2 (en) | 2022-08-09 |
| US10610542B2 (en) | 2020-04-07 |
| EP2670412A4 (en) | 2015-07-08 |
| CN103415293B (zh) | 2016-08-10 |
| US20140024614A1 (en) | 2014-01-23 |
| US20150297633A1 (en) | 2015-10-22 |
| KR20140012655A (ko) | 2014-02-03 |
| KR101840079B1 (ko) | 2018-03-19 |
| SG192238A1 (en) | 2013-09-30 |
| CA2826166A1 (en) | 2012-08-09 |
| EP2670412B1 (en) | 2018-01-03 |
| US20240156858A1 (en) | 2024-05-16 |
| MY164728A (en) | 2018-01-30 |
| AU2012212398B2 (en) | 2014-06-05 |
| US20210015849A1 (en) | 2021-01-21 |
| PT2670412T (pt) | 2018-03-20 |
| JP2014504613A (ja) | 2014-02-24 |
| US9861657B2 (en) | 2018-01-09 |
| WO2012103588A1 (en) | 2012-08-09 |
| US20180021369A1 (en) | 2018-01-25 |
| TW201309307A (zh) | 2013-03-01 |
| CN103415293A (zh) | 2013-11-27 |
| DK2670412T3 (en) | 2018-03-12 |
| EP2670412A1 (en) | 2013-12-11 |
| TWI520740B (zh) | 2016-02-11 |
| US20220362284A1 (en) | 2022-11-17 |
| AU2012212398A1 (en) | 2013-09-19 |
| US9101650B2 (en) | 2015-08-11 |
| JP5883458B2 (ja) | 2016-03-15 |
| CA2826166C (en) | 2017-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11406660B2 (en) | Treatment of bone marrow edema (OEDEMA) with polysulfated polysaccharides | |
| Raducha et al. | Tibial shaft fractures in children and adolescents | |
| Santos et al. | Cartilage lesions and ankle osteoarthrosis: review of the literature and treatment algorithm | |
| KR20200062182A (ko) | 다황화된 다당류를 이용한 골수 병리의 치료 | |
| CN104721805A (zh) | 一种用于缓解和预防关节疾病的颗粒剂及其制备方法 | |
| Toy et al. | Corticosteroid, platelet-rich plasma, and ozone injections for sinus tarsi syndrome | |
| Specchiulli et al. | Peritalar dislocations | |
| CN113288890B (zh) | N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用 | |
| AU2019226627B2 (en) | Treatment of post-operative joint pain with polysulfated polysaccharides | |
| Rodriguez et al. | Arthrodiastasis in the treatment of ankle arthritis: a case series | |
| Ada et al. | Bilateral avascular necrosis of the knee due to corticosteroid therapy in a patient with posterior inferior cerebellar anterovenous malformation Posterior İnferior Serebellar Arterio-venöz Malformasyonlu Bir Olguda Yüksek Doz Kortikosteroid Kullanımına Baǧlı Bilateral Diz Avasküler Nekrozu | |
| Gou et al. | Clinical Observation of Minimally Invasive Surgery and Conservative Treatment for Ankle Degenerative Osteoarthropathy | |
| Benlebna et al. | Delay of consolidation and bisphosphonates: two cases | |
| Isik et al. | Is External Fixation Effective in Pediatric Femur Fractures? | |
| Puri | Clinical study on the management of complex metaphyseal fractures of the tibia (proximal and distal) with hybrid external fixation |